# A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom

Source: https://onco.cc/trials/nct07123454/  
OnCo record `nct07123454` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD4512 in hodgkin lymphoma and non-hodgkin lymphoma, run by AstraZeneca, now recruiting.

## Summary

A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT07123454 by AstraZeneca, with 91 participants planned, started 2025-09-24 and due to reach its primary completion in 2028-03-01. Interventions recorded: AZD4512. Conditions listed: B-cell Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07123454
- Phase: 1/2
- Setting: A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)
- Sponsor: AstraZeneca
- Enrolled: 91

## Sources

- ClinicalTrials.gov NCT07123454: https://clinicaltrials.gov/study/NCT07123454

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [AZD4512](https://onco.cc/drugs/azd4512/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07123454.json